Combinatrial treatment of anti-High Mobility Group Box-1 monoclonal antibody and epothilone B improves functional recovery after spinal cord contusion injury

Neurosci Res. 2021 Nov:172:13-25. doi: 10.1016/j.neures.2021.04.002. Epub 2021 Apr 18.


Spinal cord injury (SCI) causes motor and sensory deficits and is currently considered an incurable disease. We have previously reported that administration of anti-High Mobility Group Box-1 monoclonal antibody (anti-HMGB1 mAb) preserved lesion area and improved locomotion recovery in mouse model of SCI. In order to further enhance the recovery, we here examined combinatorial treatment of anti-HMGB1 mAb and epothilone B (Epo B), which has been reported to promote axon regeneration. This combinatorial treatment significantly increased hindlimb movement compared with anti-HMGB1 mAb alone, although Epo B alone failed to increase functional recovery. These results are in agreement with that anti-HMGB1 mAb alone was able to decrease the lesion area spreading and increase the surviving neuron numbers around the lesion, whereas Epo B facilitated axon outgrowth only in combination with anti-HMGB1 mAb, suggesting that anti-HMGB1 mAb-dependent tissue preservation is necessary for Epo B to exhibit its therapeutic effect. Taken together, the combinatorial treatment can be considered as a novel and clinically applicable strategy for SCI.

Keywords: Axon regeneration; Contusion injury; Epothilone B; Functional recovery; High Mobility Group Box-1; Spinal cord injury.

MeSH terms

  • Animals
  • Antibodies, Monoclonal
  • Axons*
  • Epothilones
  • Mice
  • Nerve Regeneration
  • Recovery of Function
  • Spinal Cord
  • Spinal Cord Injuries* / drug therapy


  • Antibodies, Monoclonal
  • Epothilones
  • epothilone B